Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM2510, a Multi-Center, Open-Label, Dose Escalation and Cohort Expansion Phase I Clinical Study for Advanced Solid Tumors

Next Previous
Search
Trial Profile

IMM2510, a Multi-Center, Open-Label, Dose Escalation and Cohort Expansion Phase I Clinical Study for Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMM-2510 (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Ductal carcinoma; Liver cancer; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors ImmuneOnco Biopharma

    • Most Recent Events

    • 01 Aug 2024 According to an Instil Bio media release, the phase Ia dose escalation study has been completed and demonstrated multiple responses including patients with squamous non-small cell lung cancer (NSCLC) who previously failed PD-1 inhibitors.
    • 04 Jun 2024 Results (n=33; data cutoff date: 21 Dec 2023) reporting safety and preliminary anti-tumor activity data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 27 Jun 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top